Strategic partnerships Leverage existing collaborations and past financing momentum with large medical device players and pharma partners (e.g., Actelion/J&J connections, Johnson & Johnson Innovation awards) to co-develop or license on-demand NO device platforms for broader cardiovascular and pulmonary indications.

On-demand NO market Position the on-demand NO generator as a lightweight, economical alternative to compressed gas cylinders, targeting hospitals, ambulatory clinics, home care, and remote or resource-limited settings to expand adoption beyond acute care.

Clinical and reimbursement alignment Highlight potential to unlock new revenue streams by partnering on pivotal trials, payer discussions, and regulatory pathways that enable wider use of inhaled NO therapy, supported by a strong track record of funding and milestone partnerships.

Financial leverage Capitalize on substantial funding history (debt and equity totaling over $86M) and recent CFO transition to secure strategic financing for scale-up, manufacturing ramp, and go-to-market initiatives with co-investors and strategic OEMs.

Market expansion readiness Emphasize existing awards and prior collaborations to solicit pilot deployments in pulmonary hypertension, critical care, and cardiopulmonary disorders, while pointing to a scalable technology stack suitable for integration with hospital IT and compliance systems.